Amgen Palifermin BLA For Mucositis Builds On Supportive Care Franchise; Priority Review Expected

The BLA covers reduction in incidence, duration and severity of oral mucositis in patients with hematologic malignancies undergoing bone marrow transplants. Estimated patient population is 11,000 – planned supplements for solid tumor markets will bring market to 400,000.